

Middle East respiratory syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/M45F6762A54CEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: M45F6762A54CEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Middle East respiratory syndrome – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Middle East respiratory syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Middle East respiratory syndrome Understanding

Middle East respiratory syndrome: Overview

The Middle East respiratory syndrome (MERS) is a lethal zoonotic severe lung infection caused by a legal pathogen Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It was first identified in humans in Saudi Arabia and Jordan in 2012.

Coronaviruses are large (28–32 kb) single-stranded positive-sense RNA viruses. To enter host cells, MERS-CoV attaches to its receptor, dipeptidyl peptidase 4. Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Protease cleavage of the S protein is then required for virus–cell fusion and

release of genomic RNA into the cytoplasm. Viral RNA transcription and replication occurs on double membrane vesicles and other membranous structures, which are derived from the endoplasmic reticulum. MERS can be confirmed by detection of viral nucleic acid or by serology. The presence of viral nucleic acid can be confirmed either by positive real-time reverse transcription PCR on at least two specific genomic targets or by a single positive target with sequencing of a second positive PCR product. No specific drug treatment exists for MERS and supportive treatment is the mainstay of management.

'Middle East respiratory syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Middle East respiratory syndrome pipeline landscape is provided which includes the disease overview and Middle East respiratory syndrome treatment guidelines. The assessment part of the report embraces, in depth Middle East respiratory syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Middle East respiratory syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Middle East respiratory syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Middle East respiratory syndrome.

Middle East respiratory syndrome Emerging Drugs Chapters

This segment of the Middle East respiratory syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Middle East respiratory syndrome Emerging Drugs

INO-4700: Inovio Pharmaceuticals

INO -4700 is a Middle East respiratory syndrome coronavirus vaccine. Phase II clinical trials are expected to get initiated by Inovio Pharmaceuticals for INO-4700 in April, 2021.

VTP-500: Vaccitech

VTP-500 (ChAdOx1) is a vaccine candidate in Phase I clinical trials that protects people against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the novel SARS-CoV-2 coronavirus. Vaccitech's VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein to induce T cells and antibodies that block virus-host cell receptor binding and fusion or neutralize virus infection. Janssen Vaccines & Prevention B.V., the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford enter into a collaboration to develop and manufacture ChAdOx1 vaccine against Middle East Respiratory Syndrome Coronavirus.

Further product details are provided in the report

Middle East respiratory syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Middle East respiratory syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Middle East respiratory syndrome

There are approx. 10+ key companies which are developing the therapies for Middle East respiratory syndrome. The companies which have their Middle East respiratory syndrome drug candidates in the most advanced stage, i.e. Phase II include, Inovio Pharmaceuticals.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Middle East respiratory syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Middle East respiratory syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Middle East respiratory syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Middle East respiratory syndrome drugs.

Middle East respiratory syndrome Report Insights

Middle East respiratory syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Middle East respiratory syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Middle East respiratory syndrome drugs?

How many Middle East respiratory syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Middle East respiratory syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Middle East respiratory syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Middle East respiratory syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Middle East respiratory syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Middle East respiratory syndrome – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Middle East respiratory syndrome companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Middle East respiratory syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

INO-4700: Inovio Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

VTP-500: Vaccitech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical stage products

Comparative Analysis

Middle East respiratory syndrome coronavirus vaccine: Novavax

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Middle East respiratory syndrome Key Companies

Middle East respiratory syndrome Key Products

Middle East respiratory syndrome- Unmet Needs

Middle East respiratory syndrome- Market Drivers and Barriers

Middle East respiratory syndrome- Future Perspectives and Conclusion

Middle East respiratory syndrome Analyst Views

Middle East respiratory syndrome Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Middle East respiratory syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Middle East respiratory syndrome

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Middle East respiratory syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/M45F6762A54CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M45F6762A54CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970